摘要
目的分析研究将阿昔莫司和瑞舒伐他汀联合应用于糖尿病合并血脂异常患者治疗的效果。方法选择2018年10月—2019年10月在该院进行诊疗的糖尿病合并血脂异常的患者80例进行此次实验研究。这些患者按照治疗方式的不同,分成单纯使用瑞舒伐他汀治疗的对照组患者,以及采用瑞舒伐他汀和阿昔莫司联合治疗的实验组。观察两组患者的治疗前后空腹血糖(FPG)及餐后2 h血糖(2 hPG)的差异,随后统计两组各项血脂水平的变化,并统计患者的不良反应发生情况。结果干预后实验组患者治疗的FPG及2 hPG水平明显低于对照组,各项血脂水平改善较对照组改善明显,此外实验组与对照组相比,发生不良症状较少,差异有统计学意义(P<0.05)。结论阿昔莫司和瑞舒伐他汀联合治疗糖尿病合并血脂异常的效果确切,不良反应发生较少。
Objective To analyze and study the effect of combining acipimox and rosuvastatin in the treatment of patients with diabetes and dyslipidemia.Methods Eighty patients with diabetes and dyslipidemia who were diagnosed and treated in the hospital from October 2018 to October 2019 were selected for this experimental study.These patients were divided into a control group treated with rosuvastatin alone and an experimental group treated with a combination of rosuvastatin and axilimus according to different treatment methods.Observe the difference of fasting blood glucose(FPG)before and after treatment and 2 h postprandial blood glucose(2 hPG)between the two groups of patients,and then count the changes in blood lipid levels of the two groups,and count the occurrence of adverse reactions of the patients.Results After the intervention,the FPG and 2 hPG levels of the experimental group were significantly lower than those of the control group,and the improvement of various blood lipid levels was significantly better than that of the control group.In addition,the experimental group had fewer adverse symptoms compared with the control group,and the difference was statistically significant(P<0.05).Conclusion The combined treatment of acipimox and rosuvastatin in the treatment of diabetes mellitus complicated with dyslipidemia has a definite effect,with fewer adverse reactions.
作者
周颀
罗高潮
ZHOU Qi;LUO Gao-chao(Department of Endocrinology,Huanggang Central Hospital,Huanggang,Hubei Province,438000 China)
出处
《糖尿病新世界》
2021年第1期112-114,共3页
Diabetes New World Magazine
作者简介
周颀(1968-),男,本科,副主任医师,研究方向为内分泌相关疾病;通信作者:罗高潮(1980-),男,本科,主治医师,研究方向为内分泌相关,E-mail:27636186@qq.com。
